Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Ilaris (canakinumab) for the Treatment of Systemic Juvenile Idiopathic Arthritis

Drug Name (Brand / Generic)

Ilaris / canakinumab

Developed by

Novartis

Therapy Class

Monoclonal antibody

Current Indication

Systemic Juvenile Idiopathic Arthritis (SJIA)

Market Sector

Anti inflammatory

Development Status

Approved in the US
Expand
Close
Close
Close
Globaldata

Identify the key trends in the immuno-oncology market over the next two years

Close

Go Top